Aaron Davis — Boxer Capital
Long Mirati
Mirati is a targeted oncology company. The company develops drugs to treat the genetic drivers of cancer. The stock is down 80% from ATHs; “generational drawdown in biotech. The current market cap is ~$3bn with ~$1bn cash on the balance sheet. The lead drug received approval in Dec '22. The annual revenue opportunity for the drug is ~$600M and the second drug in the company’s pipeline has a 3x addressable population. The second drug is currently still in the pipeline. Call options on the rest of the pipeline.
Last updated: 2026-03-07 by automated standardization process
last updated: